战略与国际研究中心-Global-Health-Policy-in-the-Second-Obama-Term_-Chapter-3_-Malaria_9页_268kb

U.S. Priorities for Malaria Control

Core Content

The U.S. government has played a significant role in the global fight against malaria, particularly since the launch of the President's Malaria Initiative (PMI) in 2005. This initiative, along with increased contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), has led to substantial reductions in malaria-related morbidity and mortality. Malaria, a mosquito-borne disease, remains a major health and economic burden, especially in sub-Saharan Africa, where 91% of fatalities occur. Despite progress, the gains are fragile and require continued attention to maintain.

Main Points

• Malaria's Impact:

  • Malaria causes severe illness and death, particularly in children under five.
  • It affects economic growth, stability, and education, with Africa losing an estimated $12 billion annually due to direct and indirect costs.
  • Malaria absorbs 40% of health-system capacity in affected regions.

• Progress and Success:

  • From 2000 to 2010, malaria deaths declined from 755,000 to 660,000 annually.
  • The PMI has grown from $30 million in FY 2006 to $650 million in FY 2012.
  • 36 of 99 malaria-endemic countries are now moving toward elimination, though only four are in Africa.

• Challenges:

  • Drug and Insecticide Resistance:
    • Resistance to artemisinin has been found in Southeast Asia.
    • Resistance to pyrethroids (the only approved insecticide for LLINs) has been identified in 64 countries.
    • The dormant stage of Plasmodium vivax makes it more challenging to control than Plasmodium falciparum.
  • Surveillance and Quality:
    • Only 10% of global malaria cases are currently detected by surveillance systems.
    • Counterfeit and substandard drugs remain a problem, with 16 countries still allowing the use of artemisinin monotherapies in 2012.
  • Net Replacement:
    • LLINs last only 3–4 years and must be replaced, requiring efficient and cost-effective strategies.

Key Recommendations

1. Improve Use of Rapid Diagnostics

   • Expand access to rapid diagnostic tests (RDTs) to ensure only confirmed cases are treated.
   • Enhance training and policies for community health workers to use RDTs effectively.
   • Improve surveillance systems to better track and report malaria cases.

2. Innovate Finance

   • Develop new funding mechanisms, such as "malaria bonds" or performance-based loans.
   • Support country-generated financing and coordinate with the World Bank, private sector, and affected countries.
   • Ensure financial support is predictable and sustainable for program planning.

3. Adapt to the Changing Malaria Landscape

   • Update success metrics to include maintaining low case burdens, not just reducing them.
   • Address cross-border transmission and subnational challenges.
   • Focus new research on combating Plasmodium vivax.

4. Invest in Future Tools

   • Develop and scale new interventions to counter resistance.
   • Encourage coordination across sectors, such as agriculture, to support innovation in insecticides.
   • Prioritize research on better strategies and tools for malaria control.

5. Strengthen Safeguards Against Substandard Products

   • Ensure that only quality antimalarial drugs and LLINs are used.
   • Support the FDA and other agencies in technical assistance for drug regulation.
   • Encourage malaria-endemic countries to ban the sale of monotherapies.

Conclusion

U.S. leadership has been instrumental in achieving significant progress in malaria control over the past decade. However, the future success of these efforts depends on maintaining financial and political commitment, adapting strategies to new challenges, and ensuring the quality and effective use of interventions. Continued investment in research, surveillance, and partnerships will be essential to sustain and expand these gains toward malaria elimination and eradication.